RESUMEN
OBJECTIVES: While segmentectomy is considered a viable option for small peripheral non-small-cell lung cancer, its efficacy for central lesions remains uncertain. This study aimed to assess the oncological outcomes of segmentectomy for central lesions compared to peripheral ones. METHODS: We retrospectively examined 338 clinical stage IA non-small-cell lung cancer patients who underwent thoracoscopic anatomical segmentectomy at our institution from January 2013 to December 2021. Patients were divided into 2 groups based on intrapulmonary tumour location: inner two-thirds (central group, n = 82) and outer one-third (peripheral group, n = 256). RESULTS: The gender, body mass index, performance score, smoking, comorbidities and preoperative pulmonary function were similar in both groups. On computed tomography images, tumour diameter and consolidation-to-tumour ratio were comparable between the groups. The central group had significantly greater tumour-to-pleura distances [mm, 23 (18-27) vs 11 (8-14); P < 0.001], shorter margin distances [mm, 20 (15-20) vs 20 (20-20); P < 0.001] and larger resected lung volumes based on subsegment count [4 (3-6) vs 3 (3-5); P = 0.004] than the peripheral group. Surgery duration, bleeding, hospitalization or drainage period, mortality, readmission and pathological stage were equivalent between the groups. The central group showed significantly more postoperative pleural effusions (5% vs 1%; P = 0.03) than the peripheral group, with no adverse impact on postoperative pulmonary functions. During the follow-up period, local-only recurrence rates were 0% and 8% in the respective groups (Gray test P = 0.07), and total recurrence rates were 6% and 11% (Gray test P = 0.70), with no significant differences. Moreover, no significant inter-group difference in overall survival rates was observed (82% vs 93%; P = 0.15). CONCLUSIONS: Segmentectomy may be a promising therapeutic option for early-stage non-small-cell lung cancer located in the inner two-thirds of the parenchyma.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Humanos , Estudios Retrospectivos , Neumonectomía/efectos adversos , Neumonectomía/métodos , Resultado del Tratamiento , Estadificación de NeoplasiasRESUMEN
BACKGROUND: Among anatomical sublobar resection techniques for non-small cell lung cancer (NSCLC), the clinical benefit of subsegmentectomy remains unclear. We investigated whether anatomical sublobar resection including subsegmentectomy-segmental resection with subsegmental additional resection or subsegmental resection alone-is an effective and feasible surgical procedure for NSCLC. METHODS: We retrospectively reviewed data of 285 patients with clinical stage I NSCLC who underwent anatomical sublobar resection at our institution from January 2013 to March 2021 and compared surgical outcomes between patients who underwent anatomical sublobar resection including (IS; n = 50) and excluding (ES; n = 235) subsegmentectomy. RESULTS: No significant intergroup differences were noted in terms of age, sex, smoking, comorbidities, tumor size or location, consolidation tumor ratio, and preoperative pulmonary function. The IS group had more preoperative computed tomography-guided markings (34 vs. 15%; p = .004) and smaller resected lung volumes converted to the total subsegment number [3 (2-4) vs. 3 (3-6); p = .02] than the ES group. No significant differences in margin distance [mm, 20 (15-20) vs. 20 (20-20); p = .93], readmission rate (2% vs. 3%; p > .99), and intraoperative (8% vs. 7%; p = .77) or postoperative (8% vs. 10%; p = .80) complication rates were observed, and the 5-year local recurrence-free survival (91% vs. 90%; p = .92) or postoperative pulmonary function change were comparable between both groups. CONCLUSIONS: Although further investigations are required, anatomical sublobar resection including subsegmentectomy for clinical stage I NSCLC could be an acceptable therapeutic option.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Humanos , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Estadificación de Neoplasias , Neumonectomía/métodos , Estudios RetrospectivosRESUMEN
ABSTRACT: The presence of pleural adhesions increases blood loss, occurrence of pulmonary fistulation due to lung injury, and operative time and may complicate thoracoscopic surgery. Recently, it has been reported that four-dimensional computed tomography (4D-CT) synchronized with breathing predicts pleural adhesion. These studies have been performed by asking the patients to maintain a constant respiratory rhythm at the time of scanning. However, many patients face difficulty in doing so, particularly elderly individuals and patients with respiratory dysfunction. We examined the utility of 4D-CT performed while maintaining a natural breathing pattern, which reduces patient burden, in detecting pleural adhesions.A total of 36 patients with a lung tumor near the pleura underwent 4D-CT during free breathing. The migration distance between the lesion and the nearest point on the chest wall on 4D-CT was measured. A sufficient distance indicated the absence of adhesion in that area. The presence of actual adhesions was evaluated and confirmed by intraoperative thoracoscopic findings.There were 7 cases determined to have adhesion by 4D-CT, and 4 of them had actual adhesions confirmed during surgery. The sensitivity and specificity were 80.0% and 90.3%, respectively. The mean migration distance of tumors was 0.8â±â0.2âcm in the 5 cases with adhesion and 2.6â±â1.8âcm in the 31 cases without adhesion (Pâ=â.01).These results suggest that 4D-CT is a convenient and useful technique for the preoperative assessment of pleural adhesion.
Asunto(s)
Tomografía Computarizada Cuatridimensional/métodos , Neoplasias Pulmonares/diagnóstico por imagen , Enfermedades Pleurales/diagnóstico por imagen , Adherencias Tisulares/diagnóstico por imagen , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/cirugía , Masculino , Pleura/diagnóstico por imagen , Pleura/patología , Cuidados Preoperatorios , Periodo Preoperatorio , Pared Torácica , Adherencias Tisulares/patologíaRESUMEN
This article describes the first reported case of myasthenia gravis (MG) seropositive for both acetylcholine receptor antibody and low-density lipoprotein receptor-related protein 4 antibody, complicated by autoimmune polyglandular syndrome (APS) type 3. The patient exhibited myasthenic weakness restricted to the ocular muscles and ptosis. Severe clinical deterioration ensued with predominant bulbar symptoms. MG rapidly worsened, the patient was intubated, and agranulocytosis due to thiamazole was also present, so it was necessary to perform thyroidectomy with tracheostomy and thymectomy in two phases. Both the double-seropositive MG and the APS were involved in the patient's rapid deterioration.
Asunto(s)
Proteínas Relacionadas con Receptor de LDL/inmunología , Miastenia Gravis/sangre , Miastenia Gravis/inmunología , Poliendocrinopatías Autoinmunes/complicaciones , Poliendocrinopatías Autoinmunes/inmunología , Receptores Colinérgicos/sangre , Receptores Colinérgicos/inmunología , Adolescente , Adulto , Anciano , Autoanticuerpos/sangre , Femenino , Humanos , Lactante , Masculino , Adulto JovenRESUMEN
INTRODUCTION: The nodule located at the left anterior segment near the lingular segment is traditionally resected by left upper lobectomy. We performed video-assisted thoracoscopic surgery (VATS) segmentectomy and could achieve a complete resection that is minimally invasive and oncologically sufficient. PRESENTATION OF CASE: An 82-year-old woman was found to have a nodule in the left anterior segment of the lung on chest computed tomography (CT). The nodule was 1.9 cm in size and strongly suspected to be lung carcinoma. No suspicious regions of metastasis were observed; thus, we diagnosed stage IA2 and decided to perform anterior and lingular segmentectomy by VATS. DISCUSSION: Because of the location, the tumor is traditionally resected by left upper lobectomy. However, we planned a minimally invasive intervention and performed anterior and lingular segmentectomy by VATS using a CT-guided nodule marking prior to the surgery. CONCLUSION: This technique resulted in complete tumor resection with minimal adverse effects.
RESUMEN
Situs inversus totalis (SIT) is a rare anomaly. A limited number of reports document surgery for lung cancer in patients with SIT. We report the case of a 68-year-old man with SIT who underwent video-assisted thoracoscopic bisegmentectomies for synchronous double primary lung cancers. Preoperative evaluation of the pulmonary vessels and bronchus by three-dimensional computed tomography (CT) was unavailable owing to the patient's renal function disorder. However, the procedure was safely completed by adequate anatomic identification and careful operative manipulation based on plain CT study. His postoperative course was uneventful, and no recurrence has been observed 3 years after surgery.
Asunto(s)
Carcinoma de Células Escamosas/cirugía , Neoplasias Pulmonares/cirugía , Situs Inversus/complicaciones , Cirugía Torácica Asistida por Video/métodos , Anciano , Carcinoma de Células Escamosas/diagnóstico por imagen , Carcinoma de Células Escamosas/patología , Humanos , Imagenología Tridimensional , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/patología , Masculino , Recurrencia Local de Neoplasia , Tomografía de Emisión de Positrones , Cuidados Preoperatorios , Tomografía Computarizada por Rayos XRESUMEN
A 63-year-old woman was referred to our hospital due to an abnormal shadow in the right middle lung field on chest X-ray. Chest computed tomography revealed a 2.0 cm nodule in the right lateral segment of the middle lobe. The nodule was confirmed to be lung adenocarcinoma by transbronchial lung biopsy. Because the tumor was located near the incomplete interlobar fissures, resection might traditionally be performed by right upper and middle lobectomy. However, we chose a minimally invasive intervention and performed anterior, lateral, and medial segmentectomy under video-assisted thoracic surgery. This technique resulted in complete tumor resection with minimal adverse effects.
RESUMEN
INTRODUCTION: Patients with esophageal cancer frequently cannot tolerate thoracotomy due to their overall debilitated condition. Moreover, some patients have severe adhesions in the thoracic cavity. Eversion stripping of the esophagus is an option for resection in these patients. PRESENTATION OF CASE: A 64-year-old man was admitted to our institution with the chief complaint of epigastric pain. Endoscopic examination showed a protruding lesion 22cm from the incisors, with a superficial and circumferential mucosal irregularity on the distal side of the lesion. Biopsy revealed squamous cell carcinoma. Clinical stage was T1b(sm)N0M0, cStage I. In addition to the poor pulmonary status of the patient, adhesions in the intrathoracic cavity were predicted. The decision was made to perform esophageal resection without a thoracotomy. In order to ensure complete invagination of the esophagus, the esophagus was insufflated prior to stripping. The stripping process was observed with a gastroscope. During the stripping, the esophagus did not bunch up, and stripping was smooth and with minimal resistance. DISCUSSION: The stripping resection of the esophagus is an important option for the esophageal surgeon. In this case report, we describe a new eversion stripping method of the esophagus. This easy and reliable stripping method incorporates intraesophageal insufflation. CONCLUSION: The indications for blunt esophageal dissection without thoracotomy have been decreasing. On the other hand, our method seems to be useful in optimal case of stripping of esophagus.
RESUMEN
With advances of combined modality therapy, prognoses in esophageal cancer have been improving. After resection of esophageal cancer, the development of gastric tube cancer is a risk. While such cancer in an early stage can be cured endoscopically, total gastric tube resection is indicated in advanced stages. A 68-year-old man underwent subtotal esophagectomy reconstructed with a gastric tube through the retrosternal route. Gastric cancer was found one and a half years postoperatively. The gastric tube was resected without sternotomy. This is the first report of a patient undergoing resection of the gastric tube reconstructed through the retrosternal route without sternotomy.
RESUMEN
A 40-year-old woman with generalized myasthenia gravis was scheduled for extended thymectomy. The patient under general anesthesia with double-lumen intubation was placed in the supine position. A sealed 5 mm trocar and 2 sealed 12 mm trocars were inserted through the 3rd, 4th and 5th intercostal space at the both side of the anterior axillary line. Under carbon dioxide insufflations by positive pressure of 7 mmHg, thymus and fat tissue was resected completely. An operation time was 162 minutes, and blood losses during operation were 5 ml. The present method was thought to be safe and useful for conducting extended thymectomy.
Asunto(s)
Insuflación/métodos , Cirugía Torácica Asistida por Video/métodos , Timectomía/métodos , Dióxido de Carbono , Femenino , Humanos , Persona de Mediana Edad , Miastenia Gravis/cirugíaRESUMEN
A 66-year-old woman underwent nephrectomy to treat renal cell carcinoma 5 years previously. Enhanced CT to locate the tumor revealed a lesion very close to the right upper pulmonary vein. Six months later, the nodule grew to 14mm in maximum dimension and it seemed to be a varix of the right upper pulmonary vein on 3D-CT. However, pulmonary artery angiography (PAG) denied this possibility. PET-CT revealed the nodule to be positive for FDG uptake (maxSUV 2.7 in the early phase and 2.2 in the late phase), suggesting that it contained solid tissue with malignant characteristics. Eventually, right upper lobectomy was performed. The nodule was a metastatic renal cell carcinoma with extremely abundant vascular components. This conspicuous feature of the tumor appeared to mimic a pulmonary vein varix on enhanced CT scan and 3D angiogram.
Asunto(s)
Carcinoma de Células Renales/patología , Neoplasias Renales/patología , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/secundario , Venas Pulmonares , Várices/diagnóstico , Anciano , Femenino , Humanos , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos XRESUMEN
We described a case of pulmonary inflammatory myofibroblastic tumor that was resected video-assisted thoracoscopic surgery (VATS) with safety surgical margin. The legion masqueraded primary lung cancer showing invasion to neighboring lobe. Positron emission tomography (PET) was not helpful in diagnosing whether it was malignant or not. Inflammatory myofibroblastic tumor was called as inflammatory pseudotumor, formerly. Several reports, however, suggested that so called inflammatory pseudotumor was a true neoplasm rather than a proliferating tissue due to inflammatory response. It is not rare that inflammatory myofibroblastic tumor invades neighboring organ or shows relapsing after coarse margin resection. Our case would remind pulmonary physicians of its correct treatment, i.e. surgical resection with adequate safety margin.
Asunto(s)
Neoplasias Pulmonares/patología , Neoplasias de Tejido Muscular/patología , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Neoplasias de Tejido Muscular/diagnóstico , Neoplasias de Tejido Muscular/cirugía , Tomografía de Emisión de Positrones , Cirugía Torácica Asistida por Video , Tomografía Computarizada por Rayos XAsunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , ADN de Neoplasias/genética , Receptores ErbB/genética , Neoplasias Pulmonares/tratamiento farmacológico , Mutación , Inhibidores de Proteínas Quinasas/uso terapéutico , Quinazolinas/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/metabolismo , Gefitinib , Humanos , Japón/epidemiología , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/mortalidad , Tasa de Supervivencia/tendenciasRESUMEN
Thymic carcinoids are classified into three categories: (1) nonsecretory tumors, (2) hormonal secretory tumors, and (3) tumors associated with multiple endocrine neoplasia type 1. We report a rare case with adrenocorticotropic hormone secreting thymic carcinoid with multiple endocrine neoplasia type 1. Radiologic examination showed an anterior mediastinal mass and a parathyroid tumor. Blood analysis revealed high levels of parathyroid hormone and adrenocorticotropic hormone. Urine cortisol and 17-hydroxycorticoids levels were also elevated. Extended thymectomy was performed. Subsequently adjuvant radiation therapy and parathyroid tumor resection were performed. A germline mutation of exon 7 in the multiple endocrine neoplasia type 1 gene was detected and a somatic mutation of exon 9 was demonstrated in the thymic tumor.
Asunto(s)
Síndrome de ACTH Ectópico/etiología , Tumor Carcinoide/metabolismo , Neoplasia Endocrina Múltiple Tipo 1/complicaciones , Neoplasias del Timo/metabolismo , Síndrome de ACTH Ectópico/sangre , Antineoplásicos Hormonales/uso terapéutico , Tumor Carcinoide/sangre , Tumor Carcinoide/genética , Tumor Carcinoide/terapia , Terapia Combinada , Análisis Mutacional de ADN , ADN de Neoplasias/genética , Exones/genética , Rubor/etiología , Genes Supresores de Tumor , Humanos , Hipercalcemia/etiología , Masculino , Persona de Mediana Edad , Neoplasia Endocrina Múltiple Tipo 1/sangre , Octreótido/uso terapéutico , Hormona Paratiroidea/sangre , Hormona Paratiroidea/metabolismo , Neoplasias de las Paratiroides/genética , Neoplasias de las Paratiroides/metabolismo , Neoplasias de las Paratiroides/terapia , Paratiroidectomía , Neoplasias Pleurales/secundario , Neoplasias Pleurales/cirugía , Radioterapia Adyuvante , Timectomía , Neoplasias del Timo/sangre , Neoplasias del Timo/genética , Neoplasias del Timo/terapiaRESUMEN
Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy. A quick and sensitive method with large throughput is required to utilize the information to determine whether the molecular targeted therapy should be applied for the particular NSCLC patients. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 94 NSCLC patients using the TaqMan PCR assay. We have also genotyped the EGFR mutations status in additional 182 NSCLC patients, as well as 63 gastric, 95 esophagus and 70 colon carcinoma patients. In 94 NSCLC samples, the result of the TaqMan PCR assay perfectly matched with that of the sequencing excluding one patient. In one sample in which no EGFR mutation was detected by direct sequencing, the TaqMan PCR assay detected a mutation. This patient was a gefitinib responder. In a serial dilution study, the assay could detect a mutant sample diluted in 1/10 with a wild-type sample. Of 182 NSCLC samples, 46 mutations were detected. EGFR mutation was significantly correlated with gender, smoking status, pathological subtypes, and differentiation of lung cancers. There was no mutation detected by the TaqMan PCR assay in gastric, esophagus and colon carcinomas. TaqMan PCR assay is a rapid and sensitive method of detection of EGFR mutations with high throughput, and may be useful to determine whether gefitinib should be offered for the treatment of NSCLC patients. The TaqMan PCR assay can offer us a complementary and confirmative test.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/genética , Receptores ErbB/genética , Neoplasias Pulmonares/genética , Mutación , Reacción en Cadena de la Polimerasa/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias del Colon/genética , Clorhidrato de Erlotinib , Neoplasias Esofágicas/genética , Femenino , Gefitinib , Genotipo , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Quinazolinas/uso terapéutico , Sensibilidad y Especificidad , Neoplasias Gástricas/genéticaRESUMEN
BACKGROUND: Endoscopic thoracic sympathectomy has been considered an effective treatment for palmar hyperhidrosis. However, the extent of resection has not been determined in terms of efficacy and complications. We compared the efficacy and complications of 2-ganglion and single-ganglion resection in patients with palmar hyperhidrosis. METHODS: From 1995 to 2000, 75 patients underwent resection of thoracic ganglion T2 and T3. From 2000 to 2003, 67 patients underwent resection of only the T2 ganglion. Eighty of the 142 patients (56%) answered a detailed questionnaire, the results of which were analyzed. RESULTS: Gender, age, family history, and distribution of sweating were similar in both groups. Recurrence rates 1 and 2 years after endoscopic thoracic ganglionectomy were between 0% and 3% in T2 and T3 resection, and between 15% and 19% in T2 resection only. In the combined T2 and T3 resection group, 100% of patients noticed compensatory sweating; in T2 resection, 90% of patients noticed compensatory sweating. As for rates of satisfaction, T2 and T3 resection was superior to T2 resection. CONCLUSIONS: High recurrence rates of palmar hyperhidrosis after single-ganglion resection are reported in the present study. Two-ganglion resection is a superior surgical method to prevent recurrence of palmar hyperhidrosis.
Asunto(s)
Endoscopía , Ganglios Simpáticos/cirugía , Hiperhidrosis/cirugía , Simpatectomía/métodos , Adolescente , Adulto , Femenino , Mano/inervación , Humanos , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Complicaciones Posoperatorias , Vértebras TorácicasRESUMEN
Using the enzyme immunoassay for epidermal growth factor receptor (EGFR), we investigated whether serum EGFR levels could be used as a predictor of the development and extension of thymoma. Serum samples were collected from 31 patients with thymoma and 16 patients with nonmalignant thoracic disease before clinical treatment. There was no difference between the serum EGFR levels of the patients with thymoma and the nonmalignant controls, being 49.1 +/- 136.3 and 22.6 +/- 7.3 fm/ml, respectively ( P = 0.11). However, patients with stage IV thymoma had significantly higher EGFR levels than those with stage I or stage II thymoma, the respective values being 127.8 +/- 243.9, 10.9 +/- 9.2 ( P = 0.02), and 19.7 +/- 10.6 ( P = 0.0433) fm/ml. The serum EGFR levels were similar in the pathological subtypes. These findings suggest that serum EGFR levels may serve as a marker that could be used as a diagnostic indicator of the invasion of thymoma.
Asunto(s)
Biomarcadores de Tumor/sangre , Receptores ErbB/sangre , Timoma/sangre , Neoplasias del Timo/sangre , Humanos , Invasividad Neoplásica , Estadificación de Neoplasias , Timoma/patología , Neoplasias del Timo/patologíaRESUMEN
Intravenous endostatin gene transfection results in tumor suppression in a murine pulmonary metastasis model. We transfected the endostatin gene at different times, in order to achieve an optimal protective effect. pST2-Endo encoding murine endostatin was injected in a complex with cationic lipid. Pulmonary metastases were caused by intravenous injection of murine fibrosarcoma cells. Mice were observed for 14 days following fibrosarcoma cell inoculation (FSI). In the study groups, the animals were transfected with pST2-Endo at three different times: 2 days before and 3 and 7 days after FSI. In the group transfected with pST2-Endo 2 days before FSI, the weights of the lungs and tumor-occupied area ratio were significantly less than in the other groups. Significant inhibition of tumor neovascularization was documented by means of CD31 immunohistochemistry. The effect of repeated endostatin transfection on survival after FSI was determined. Animals repeatedly transfected with the endostatin gene survived significantly longer than the groups treated with a single endostatin gene transfection. A stable endostatin-expressing fibrosarcoma transfectant was created and tested for migration and invasion. Compared with controls, endostatin expression reduced migration and invasion by 15%. It is concluded that endostation gene transfection before FSI and repeated transfection thereafter results in significant tumor suppression.
Asunto(s)
Endostatinas/genética , Fibrosarcoma/genética , Terapia Genética , Lípidos , Neoplasias Pulmonares/genética , Transfección , Animales , Supervivencia Celular/genética , Endostatinas/biosíntesis , Endostatinas/inmunología , Fibrosarcoma/patología , Fibrosarcoma/terapia , Vectores Genéticos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/prevención & control , Neoplasias Pulmonares/secundario , Masculino , Ratones , Ratones Endogámicos C3H , Neovascularización Patológica/genética , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/biosíntesis , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/inmunología , Transfección/métodosRESUMEN
Recently Smac/DIABLO (second mitochondria-derived activator of caspase) has been identified as a proapoptotic protein that inhibits IAPs (inhibitors of apoptosis proteins). Smac is expressed ubiquitously in many organs, including the lung. Here we evaluated the expression of Smac mRNA with real-time reverse-transcription PCR in 88 primary lung cancers and matched normal tissues. Smac mRNA expression in tumor tissues was significantly lower than that in normal tissues (p<0.0001). In squamous cell carcinomas, Smac mRNA expression was significantly lower than that in adenocarcinomas (p=0.0072). Smac mRNA expression in T2-T4 tumors was significantly lower than that in T1 tumors (p=0.0006). The expression of Smac in the tumors of smokers was lower than that in the tumors of non-smokers (p=0.0011). The prognosis of patients with a tumor exhibiting a low expression of Smac mRNA was worse than that in those with a tumor exhibiting high Smac mRNA expression (log-rank test, p=0.047). These results indicate that Smac expression may play a role in the carcinogenesis, progression, and prognosis of primary lung cancer.
Asunto(s)
Biomarcadores de Tumor/metabolismo , Proteínas Portadoras/metabolismo , Neoplasias Pulmonares/diagnóstico , Proteínas Mitocondriales/metabolismo , Proteínas Reguladoras de la Apoptosis , Proteínas Portadoras/genética , Femenino , Expresión Génica , Humanos , Inmunoquímica , Péptidos y Proteínas de Señalización Intracelular , Neoplasias Pulmonares/patología , Masculino , Proteínas Mitocondriales/genética , Pronóstico , ARN Mensajero/metabolismo , Estudios RetrospectivosRESUMEN
Cten is a recently isolated gene, which has homology with tensin suggesting that it is a focal adhesion molecule. Tensin family proteins play an important role in cell motility. We attempted to determine the influence of cten expression on clinicopathological features in patients with lung cancer who had undergone surgery. Expression of cten messenger RNA was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) in 89 lung carcinomas and adjacent histological normal lung samples using LightCycler. Cten/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression was not significantly different between lung cancer tissue (1.479+/-2.060) and normal lung tissue (1.528+/-1.592, P=0.8267). There was no relationship between cten/GAPDH expression and age, gender or N-status. However, tumor/normal ratio (T/N ratio) of cten/GAPDH expression was significantly higher in stage II-IV lung cancer (3.113+/-6.493) when compared with stage I lung cancer (1.237+/-1.820, P=0.0316). T/N ratio of cten/GAPDH expression was significantly higher in T4 lung cancer (4.612+/-9.726) when compared with T1 lung cancer (0.896+/-0.860, P=0.0252), and T2 lung cancer (1.636+/-2.066, P=0.0470), respectively. Thus cten/GAPDH mRNA expression has been correlated with evidence of tumor progression in terms of T and overall stage of lung cancer. Alternatively, cell motility or migration might play a role in progression of lung cancer.